



Check for updates

## METHOD ARTICLE

**REVISED** Estimating the contribution of studies in network meta-analysis: paths, flows and streams [version 2; referees: 2 approved, 1 approved with reservations]Theodoros Papakonstantinou <sup>1\*</sup>, Adriani Nikolakopoulou <sup>1\*</sup>, Gerta Rücker <sup>2</sup>, Anna Chaimani<sup>3</sup>, Guido Schwarzer <sup>2</sup>, Matthias Egger<sup>1</sup>, Georgia Salanti <sup>1</sup><sup>1</sup>Institute of Social and Preventative Medicine (ISPM), University of Bern, Bern, Switzerland<sup>2</sup>Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany<sup>3</sup>Paris Descartes University, INSERM, UMR1153 Epidemiology and Statistics, Sorbonne Paris Cité Research Center (CRESS), METHODS Team; Cochrane France, Paris, France

\* Equal contributors

**v2** First published: 18 May 2018, 7:610 (doi: [10.12688/f1000research.14770.1](https://doi.org/10.12688/f1000research.14770.1))  
Latest published: 03 Sep 2018, 7:610 (doi: [10.12688/f1000research.14770.2](https://doi.org/10.12688/f1000research.14770.2))**Abstract**

In network meta-analysis, it is important to assess the influence of the limitations or other characteristics of individual studies on the estimates obtained from the network. The percentage contribution matrix, which shows how much each direct treatment effect contributes to each treatment effect estimate from network meta-analysis, is crucial in this context. We use ideas from graph theory to derive the percentage that is contributed by each direct treatment effect. We start with the 'projection' matrix in a two-step network meta-analysis model, called the **H** matrix, which is analogous to the hat matrix in a linear regression model. We develop a method to translate **H** entries to percentage contributions based on the observation that the rows of **H** can be interpreted as flow networks, where a stream is defined as the composition of a path and its associated flow. We present an algorithm that identifies the flow of evidence in each path and decomposes it into direct comparisons. To illustrate the methodology, we use two published networks of interventions. The first compares no treatment, quinolone antibiotics, non-quinolone antibiotics and antiseptics for underlying eardrum perforations and the second compares 14 antimanic drugs. We believe that this approach is a useful and novel addition to network meta-analysis methodology, which allows the consistent derivation of the percentage contributions of direct evidence from individual studies to network treatment effects.

**Keywords**

indirect evidence, percentage contributions, projection matrix, flow networks

**Open Peer Review**

Referee Status: ? ✓ ✓

Invited Referees

1 2 3

**REVISED****version 2**published  
03 Sep 2018**version 1**published  
18 May 2018

?

report

✓

report

✓

report

- 1 **Jochem König** , Johannes Gutenberg University Medical Center, Germany
- 2 **Annette M. O'Connor** , Iowa State University, USA
- 3 **John R. Thompson** , University of Leicester, UK

**Discuss this article**

Comments (0)

**Corresponding author:** Adriani Nikolakopoulou ([nikolakopoulou.adriani@gmail.com](mailto:nikolakopoulou.adriani@gmail.com))

**Author roles:** **Papakonstantinou T:** Conceptualization, Formal Analysis, Methodology, Software, Writing – Original Draft Preparation, Writing – Review & Editing; **Nikolakopoulou A:** Conceptualization, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Rücker G:** Investigation, Methodology, Writing – Review & Editing; **Chaimani A:** Software, Writing – Review & Editing; **Schwarzer G:** Software, Writing – Review & Editing; **Egger M:** Supervision, Writing – Review & Editing; **Salanti G:** Conceptualization, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** TP received funding from a Campbell Collaboration Method Grant [grant no. CMG2.04].

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2018 Papakonstantinou T *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

**How to cite this article:** Papakonstantinou T, Nikolakopoulou A, Rücker G *et al.* **Estimating the contribution of studies in network meta-analysis: paths, flows and streams [version 2; referees: 2 approved, 1 approved with reservations]** *F1000Research* 2018, 7:610 (doi: [10.12688/f1000research.14770.2](https://doi.org/10.12688/f1000research.14770.2))

**First published:** 18 May 2018, 7:610 (doi: [10.12688/f1000research.14770.1](https://doi.org/10.12688/f1000research.14770.1))

**REVISED Amendments from Version 1**

This revised version of this manuscript includes suggestions and additions suggested by the first reviewer, Dr. Jochem König. Our improvements include the following:

1. Percentage contributions are now distributed to single trials according to their weights from direct meta-analyses. Thus, study percentage contributions can now be derived. [Figure 3](#) and [Table 4](#) have been updated accordingly.
2. We have now added a paragraph in the Discussion to highlight the limitations of the presented method and to clarify that the scope of this paper is not to quantify the impact of within-study bias on the NMA estimates.
3. We re-arranged [Figure 1](#) and [Figure 2](#) such that source is on the left and sink on the right.
4. [Supplementary file 3](#) has been modified.

See referee reports

## Introduction

Decision making around multiple alternative healthcare interventions is increasingly based on meta-analyses of a network of relevant studies, which contribute direct and indirect evidence to different treatment comparisons<sup>1,2</sup>. Limitations in the design and flaws in the conduct of studies synthesized in network meta-analysis (NMA) reduce the confidence in the results: a treatment comparison in the network may be directly or indirectly informed by studies at high risk of bias. A relative treatment effect from NMA (hereafter the NMA effect estimate) is estimated as a linear combination of the available direct estimates of the treatment effect (i.e. the results from pairwise meta-analyses) and the indirect evidence on the treatment effect.

Salanti *et al.* suggested that in order to assess the impact of study deficiencies on an NMA effect estimate, the limitations of studies contributing to direct estimates should be considered jointly, taking into account their relative contribution to the overall NMA effect estimate<sup>3</sup>. The percentage contribution matrix plays a key role in this approach: a matrix that shows how much each direct effect contributes to the estimation of the NMA effect.

The percentage contribution matrix is derived from the absolute contribution matrix. The absolute contributions of direct effects to an NMA effect is the projection matrix from a two-step NMA model<sup>4,5</sup>. In the first stage, all direct effects are derived from pairwise meta-analyses. In the second stage, the NMA effect estimates are produced as a linear combination of the derived direct effects. The respective projection matrix is called the **H** matrix and it is analogous to the hat matrix in a linear regression model. The elements in the **H** matrix can be viewed as generalized weights from pairwise meta-analysis, but they do not add up to 1 and depend on the precision of the available studies, the degree of between-study heterogeneity and the network structure.

To translate the entries of the **H** matrix into percentage contributions, Salanti *et al.* suggested normalizing the absolute entries of each row of **H** and interpret them as percentages<sup>3</sup>. However, **H** represents the flow of evidence in different paths; the weight of each path is assigned to each direct effect involved. Thus,

ignoring the multiple occurrences of the same values by taking standardized absolute values is incorrect. In particular, such a process overestimates the contribution of comparisons involved in long paths and underestimates the weights of the shortest paths. In this paper, we address this issue and present a method that properly translates the entries of the **H** matrix into percentages. The methodology is based on the observation that the rows of the **H** matrix can be interpreted as flow networks<sup>4,6</sup>.

## Motivating example

To illustrate the ideas presented in this paper, we will use a network of topical antibiotics for the treatment of chronic otitis media with ear discharge in patients with eardrum perforations<sup>7</sup>. This network was used in Salanti *et al.*<sup>3</sup> and compares no treatment (*x*), quinolone antibiotic treatment (*y*), non-quinolone antibiotic treatment (*u*) and antiseptic treatment (*v*)<sup>7</sup>. The study outcome was the proportion of patients with persistent discharge from the ear after 1 week, measured using the odds ratio (OR). The network plot shown in [Figure 1a](#) shows that direct evidence exists for all comparisons except *u* versus *x* (non-quinolone antibiotic versus no treatment).

In order to assess the confidence that should be placed in an NMA effect estimate, Salanti *et al.* suggested considering the quality of all pieces of evidence that contributed to it<sup>3</sup>. For example, the studies directly comparing '*u* versus *v*' were judged to be at high risk of bias; however, in order to judge the quality of the NMA effect estimate of '*u* versus *v*', we need to consider the amount of data that these studies contributed to its estimation.


## Methods

We first present the random-effects two-stage NMA model first described by Lu *et al.*<sup>5</sup>. We will employ a simplified version of the **H** matrix described by König *et al.*<sup>4</sup> that does not take into account the correlation induced by multi-arm trials. We ignore this correlation for the sake of ease of interpretation of the entries in the **H** matrix; we discuss implications of multi-arm trials at the end of the Methods section. Taking advantage of previous findings on how the flow of evidence can be considered in NMA<sup>4,6</sup>, we present an algorithm to decompose the flow in a network and subsequently approximate the percentage contributions of direct effect estimates for each NMA effect estimate.

### Two-stage network meta-analysis model

Consider a network of *T* competing treatments. The set of treatments is denoted by  $V = \{x, y, u, v, \dots\}$  and let *x* denote the reference treatment. The number of NMA effects to be estimated is  $\binom{T}{2}$  but the estimation of *T* – 1 effects allows the derivation of the remaining effects via linear combination. We collect the *T* – 1 effects against the reference treatment *x* in a vector of basic parameters  $\theta = (\theta_{xy}, \theta_{xu}, \theta_{xv}, \dots)'$ . In the case of a dichotomous outcome,  $\theta$  is the parameter vector of all log-ORs compared to the common reference treatment *x*.

We assume that the distribution of effect modifiers is similar across comparisons and thus the transitivity assumption is plausible. The consistency assumption refers to the statistical manifestation of transitivity and implies that all sources of



**Figure 1.** Network plot for the network of topical antibiotics without steroids for chronically discharging ears (a), comparison graph corresponding to the  $h^{xy}$  row of  $H$  matrix (b), flows  $f_{uv}$  with respect to the ‘x versus y’ network meta-analysis treatment effect are indicated along the edges), streams (c) and percentage contributions of each direct comparison (d).  $x$ , no treatment;  $y$ , quinolone antibiotic;  $u$ , non-quinolone antibiotic;  $v$ , antiseptic.

evidence are in agreement; this is expressed via the consistency equations

$$\theta_{uv} = \theta_{xv} - \theta_{xu}, \text{ for all } u, v \in V$$

Let us denote the number of comparisons with direct data (that is, at least one direct study) with  $D$ . For simplification, consider that there are no multi-arm studies. At the first stage of the NMA model, direct effects are estimated, using random-effects pairwise meta-analyses. The estimates of the direct effects are collected in a column vector  $\hat{\theta}^D$  of length  $D$ ; their estimated variances are collected in a diagonal  $D \times D$  matrix  $V^D$ . At the second stage, the NMA effects are estimated as

$$\hat{\theta}^N = H\hat{\theta}^D \quad \text{Equation 1}$$

where  $H$  is

$$H = Y(X'(V^D)^{-1}X)^{-1}X'(V^D)^{-1} \quad \text{Equation 2}$$

Matrix  $X$  is a  $D \times (T - 1)$  design matrix expressing the linear relationships between the available direct effects and the basic parameters and  $Y$  is a  $\binom{T}{2} \times (T - 1)$  design matrix that links the NMA estimates with the basic parameters. Note that  $X$  is identical to  $Y$  only when there are direct studies for all treatment comparisons in the network.

Matrix  $H$  is of dimensions  $\binom{T}{2} \times D$  and describes the influence of each direct effect (specified in the column) to an NMA effect (specified in the row). As Equation 2 implies,  $H$  is derived as a function of the variances of the direct effects  $\hat{\theta}^D$  and the network structure; therefore, the exact (absolute) contribution of each direct comparison depends on the precision of the available direct data and the comparison’s connectivity to the rest of the network. Note that it resembles the hat matrix in a linear regression model.

Let us focus on a single row of the  $H$  matrix which, say, corresponds to the NMA effect estimate of ‘x versus y’ and is denoted by  $h^{xy}$ . Elements of  $h^{xy}$  are denoted by  $h_{uv}^{xy}$  and show the absolute contribution of the direct effect  $\hat{\theta}_{uv}^D$  indicated in the subscript (‘u versus v’) to the ‘x versus y’ NMA effect  $\hat{\theta}_{xy}^N$ . Consider our motivating example which examines the set of treatments  $V = \{x, y, u, v\}$ . Equation 1 implies that the NMA treatment effect for the ‘x versus y’ comparison is derived as a linear combination of the direct meta-analyses

$$\hat{\theta}_{xy}^N = h_{xy}^{xy} \hat{\theta}_{xy}^D + h_{yv}^{xy} \hat{\theta}_{yv}^D + h_{xv}^{xy} \hat{\theta}_{xv}^D + h_{yu}^{xy} \hat{\theta}_{yu}^D + h_{uv}^{xy} \hat{\theta}_{uv}^D \quad \text{Equation 3}$$

The element  $h_{xy}^{xy}$  represents the absolute but also the percentage contribution  $p_{xy}^{xy}$  of the direct evidence for the particular NMA effect. Assuming that the comparison ‘x versus y’ is not part of any multi-arm study, the evidence to derive the NMA effect estimate can be portioned into direct and indirect estimates

$$\hat{\theta}_{xy}^N = h_{xy}^{xy} \hat{\theta}_{xy}^D + (1 - h_{xy}^{xy}) \hat{\theta}_{xy}^I \quad \text{Equation 4}$$

with  $\hat{\theta}_{xy}'$  denoting the indirect effect for the 'x versus y' comparison; hence  $p_{xy}^{xy} = h_{xy}^{xy}$ . While the percentage contribution of each direct effect to its NMA effect can be obtained as the diagonal of the  $\mathbf{H}$  matrix, the percentage contributions of other direct relative effects via indirect evidence (e.g. the  $p_{uv}^{xy}$  percentage contribution of  $\hat{\theta}_{uv}^D$  to  $\hat{\theta}_{xy}^N$ ) cannot be easily derived from the absolute contributions (that is, from  $h_{uv}^{xy}$ ). In the next section we will present how the absolute contributions  $h_{uv}^{xy}$  could be translated to percentage contributions  $p_{uv}^{xy}$ .

To explain the method, we will continue focusing on one row of the  $\mathbf{H}$  matrix, say  $\mathbf{h}^{xy}$ , corresponding to the 'x versus y' comparison. **Box 1** includes the definitions, along with the notation, of some of the notions used in this paper.

### Box 1. Definitions

#### Set of vertices

The set of vertices is defined as the set of treatments examined in the network,  $V = \{x, y, u, v \dots\}$ .

#### Set of directed edges

The set of directed edges  $E$  is defined as the set of direct comparisons respecting the signs of the entries of  $\mathbf{h}^{xy}$ , the row of the  $\mathbf{H}$  matrix corresponding to the 'x versus y' comparison. Edges are given a direction upon the definition of flows; the network itself corresponds to an undirected graph.

#### Set of flows

The set of flows is defined as  $F = \{f_{uv}, \forall uv \in E\}$  where  $f_{uv}$  is equal to  $|h_{uv}|$ .

#### Comparison graph

A comparison graph is defined as a graph  $G_{xy} = (V, E, F)$  constructed from a row of the  $\mathbf{H}$  matrix,  $\mathbf{h}^{xy}$ ; its definition derives from a set of vertices  $V$ , a set of edges  $E$ , and a set of flows,  $F$ .

#### Source

Source is defined as a vertex with no incoming edges.

#### Sink

Source is defined as a vertex with no outgoing edges.

#### Path

A path  $\pi_i$  is defined as a sequence of connected directed edges belonging to  $E$ .

#### Stream

A stream  $S_i$  is defined as the composition of a path and its associated flow,  $S_i = (\varphi_i, \pi_i)$ , with  $i = 1, \dots, I$  where  $I$  is the total number of streams.

### Comparison graph

König *et al.* showed that every row of the  $\mathbf{H}$  matrix,  $\mathbf{h}^{xy}$ , can be interpreted as a flow network with source  $x$  and sink  $y$ , and visualised in a directed acyclic graph (DAG)<sup>4</sup>. Thus, we create a graph  $G_{xy} = (V, E, F)$  from  $\mathbf{h}^{xy}$ ; its definition derives from a set of vertices  $V$ , a set of edges  $E$ , and a set of flows,  $F$ . The set of vertices is defined as the set of treatments examined in the network,  $V = \{x, y, u, v \dots\}$ . Set  $E$  is defined as a set of directed edges that correspond to observed direct comparisons respecting the signs of the entries of  $\mathbf{h}^{xy}$ . To simplify the notation, we

drop from now on all superscripts assuming they all refer to  $xy$ . Then, the set  $E$  contains  $uv$  if  $h_{uv} > 0$  or contains  $vu$  if  $h_{uv} < 0$ . The set of flows is defined as  $F = \{f_{uv}, \forall uv \in E\}$  where  $f_{uv}$  is equal to  $|h_{uv}|$ .

The following conditions hold for the elements of set  $F$  (see **Supplementary File 1** for proof):

- a. The sum of outflows of node  $x$  (source) is 1

$$\sum_{xu \in E} f_{xu} = 1$$

- b. The sum of inflows of node  $y$  (sink) is 1

$$\sum_{uy \in E} f_{uy} = 1$$

- c. The flow passing through each internal node (any node except  $x$  or  $y$ ) is conserved

$$\forall z \in V \setminus \{x, y\}, \sum_{vz \in E} f_{vz} = \sum_{uz \in E} f_{zu}$$

- d.  $G_{xy}$  is acyclic; there is no path (sequence of edges) that visits the same vertex twice.

Consider, for example, the graph  $G_{xy}$  in **Figure 1b**, which corresponds to the  $xy$  comparison of the network of four treatments of **Figure 1a**. The set of vertices is  $V = \{x, y, u, v\}$  and the set of directed edges is  $E = \{xy, xv, vy, vu, uy\}$ . Flows  $f_{uv}$  are given along the edges; their numerical values are equal to the respective absolute entries of  $\mathbf{h}^{xy}$  and the direction of their corresponding edge is indicated in the subscript. As properties (a) to (d) imply, the arrows in **Figure 1b** indicate that the outflows of  $x$ , as well as the inflows of  $y$ , equal 1, and that the inflows equal the outflows in the intermediate nodes  $u$  and  $v$ .

### Streams

In **Figure 1b** there are three different paths from  $x$  to  $y$ , one based on direct evidence,  $\{xy\}$ , and two based on indirect evidence,  $\{xv, vy\}$  and  $\{xv, vu, uy\}$ . A path is a sequence of connected directed edges belonging to  $E$ , and we denote it as  $\pi_i$ . As property (d) implies, each node occurs at most once in  $\pi_i$ . Then, given the above properties of  $f_{uv}$ , we can assign a flow  $\varphi_i$  to each path  $\pi_i$ . Flow  $\varphi_i$  is equal to the smallest  $f_{uv}$  in the path  $\pi_i$ . **Figure 1c** shows the three paths from  $x$  to  $y$ ;  $\pi_1$ ,  $\pi_2$  and  $\pi_3$ , and their corresponding flows. Path  $\pi_1$  corresponds to  $xy$  and its flow,  $\varphi_1$ , equals the flow of the single edge in path,  $f_{xy} = 0.635$ . Path  $\pi_2$  is constituted from two edges,  $xv$  and  $vy$ ; thus, flow  $\varphi_2 = \min(f_{xv}, f_{vy}) = 0.251$ . The flow corresponding to the third path  $\pi_3$  is  $\varphi_3 = \min(f_{xv}, f_{vu}, f_{uy}) = 0.114$ .

We define a stream,  $S_i$ , as the composition of a path and its associated flow,  $S_i = (\varphi_i, \pi_i)$  with  $i = 1, \dots, I$  where  $I$  is the total number of streams; here  $I = 3$ . Note that it holds  $\sum_{i=1}^I \varphi_i = 1$ .

### Percentage contributions of direct comparisons

In order to assign percentage contributions to each direct comparison, we need to split each stream's flow to the involved



edges in the stream's path. It can be shown that an NMA effect is a linear combination of the direct effects combined within paths. More specifically, Equation 3 can be re-written as

$$\hat{\theta}_{xy}^N = \varphi_1 \hat{\theta}_{xy}^D + \varphi_2 (\hat{\theta}_{xv}^D - \hat{\theta}_{yv}^D) + \varphi_3 (\hat{\theta}_{xv}^D - \hat{\theta}_{uv}^D - \hat{\theta}_{yu}^D) \quad \text{Equation 5}$$

with  $\sum_{i=1}^3 \varphi_i = 1$ . Equation 5 represents  $\hat{\theta}_{xy}^N$  as a weighted sum of direct and two indirect effect estimates; the effects are stochastically interdependent and, hence, their aggregation is different from the aggregation of studies in a pairwise meta-analysis.

To approximate the percentage contributions per comparison, we suggest dividing  $\varphi_i$  by the length of the respective path  $\pi_i$ ,  $\#\pi_i$ . This will leave the percentage contribution of the direct evidence of the  $\mathbf{H}$  matrix and assign to each comparison involved in an indirect route a portion of the respective stream's flow. Note that directed edges might be involved in more than one path; we thus define the percentage contribution of an edge  $uv$  as

$$p_{uv} = \sum_{\forall i \text{ where } uv \in \pi_i} \varphi_i / \#\pi_i \quad \text{Equation 6}$$

Figure 1d shows the derivation of the percentage contributions of each direct comparison in the network of topical antibiotics. Hence, from the row of the  $\mathbf{H}$  matrix (0.635, 0.365, -0.114, -0.251, -0.114), which shows the absolute contributions of the direct effects  $\hat{\theta}_{xy}^D, \hat{\theta}_{xv}^D, \hat{\theta}_{yv}^D, \hat{\theta}_{uv}^D, \hat{\theta}_{yu}^D$  to  $\hat{\theta}_{xy}^N$ , we approximated their percentage contribution as 63.5%, 16.4%, 3.8%, 12.6% and 3.8%, respectively.

#### Algorithm to decompose flows into percentage contributions

In this section, we present an iterative algorithm that generalizes the process outlined above to derive percentage contributions of each direct effect to the estimation of a 'x versus y' NMA effect. We start by defining a graph  $G_{xy}$  from  $\mathbf{h}^{xy}$ .

The algorithm is described as follows:

0. Set initial graph  $G_0 = (V, E_0, F_0) = G_{xy}$ .  $E_0$  contains  $uv$  if  $h_{uv} > 0$  or contains  $vu$  if  $h_{uv} < 0$ . The set of flows is  $F_0 = \{f_{0,uv} \mid uv \in E_0\}$ ; numerical values of  $f_{0,uv}$  are equal to  $h_{uv}$ .

Then, repeat the process below  $I$  times, equal to the number of streams in  $G_i$ , until  $E_i = \{\emptyset\}$ .

1. In  $G_{i-1}$ , find the shortest path from  $x$  to  $y$ ,  $\pi_i$ , and define its flow as  $\varphi_i = \min\{f_{i-1,uv}, uv \in \pi_i\}$ . Then, use  $\pi_i$  and  $\varphi_i$  to define the stream  $S_i = (\varphi_i, \pi_i)$ .
2. Recalculate the flow of edges  $uv \in \pi_i$  by subtracting  $\varphi_i$  from the flow of the edges of the stream found:  $f_{i,uv} = f_{i-1,uv} - \varphi_i \forall uv \in \pi_i$ . The flow of the rest of the edges that do not belong to  $\pi_i$  remain unchanged:  $f_{i,uv} = f_{i-1,uv} \forall uv \notin \pi_i$ .
3. Define  $E_i$  as the set of edges  $uv$  for which  $f_{i,uv} > 0$ ; this is  $E_{i-1}$  after removing the edges with zero flow,  $E_i = E_{i-1} \setminus \{uv \mid f_{i,uv} = 0\}$ . Collect  $f_{i,uv}$  to form the set  $F_i = \{f_{i,uv} \mid uv \in E_i\}$ .

4. If  $E_i \neq \{\emptyset\}$  define  $G_i = (V, E_i, F_i)$  and go to step 1.

When the algorithm terminates, all streams  $S_i = (\varphi_i, \pi_i)$  have been identified and Equation 6 is used to derive the percentage contributions  $p_{uv}$ .

Repeating the same process for all NMA effects, we derive all  $p_{uv}^{xy}$  and collect them in a matrix  $\mathbf{P}$  of the same dimensions as  $\mathbf{H}$ . The presented algorithm could be described as a reverse maximum flow Edmonds Karp algorithm<sup>8</sup>, but instead of adding we remove augmenting paths.

It is possible that multiple shortest paths exist; in this case, the order in which one chooses such a path could in principle result in different percentage contributions per comparison. We can, thus, use the following modification in the algorithm to impose consistency. Instead of selecting the shortest path, we assign cost values  $c_{i,uv}$  to each edge  $uv$  as follows:  $c_{i,uv} = 2 - f_{i-1,uv}$ . Then, we select the path from  $x$  to  $y$  with the minimum cost across comparisons included in  $\pi_i$ . The definition of the cost values  $c_{i,uv}$  assures that paths are selected from shortest to longest and removes any ambiguity regarding the selection of paths.

The starting point for the developed algorithm was a simplified version of the  $\mathbf{H}$  matrix that does not consider the correlation induced by multi-arm trials. Alternatively, one could use the  $\mathbf{H}$  matrix as described by König *et al.*<sup>4</sup> that extends the definition of the matrix for multi-arm designs. Note that any matrix whose rows can be interpreted as flow networks can be used as the starting point of the algorithm.

Calculations in this paper were performed using R.

#### Application

We apply the algorithm described above to the network of topical antibiotics<sup>7</sup>.

#### Percentage contributions of direct relative treatment effects to the estimation of the NMA effect between non-quinolone antibiotic and no treatment

Direct effects are obtained using the random effects model and the  $\mathbf{H}$  matrix of dimension 6x5 is calculated using Equation 2. The  $\mathbf{H}$  matrix, along with NMA effects, is given in Table 1.

We begin by applying step 0 of the algorithm. We construct the network  $G_0 = G_{xy} = (V, E_0, F_0)$  with source  $x$  and sink  $y$  corresponding to row  $\mathbf{h}^{xy}$ . The set of vertices is  $V = \{x, y, u, v\}$  and the set of directed edges, taking into account the signs of the elements of  $\mathbf{h}^{xy}$ , is  $E_0 = \{xy, xv, yv, vu, uy\}$ . The set of flows is  $F_0 = \{f_{0,uv} \mid uv \in E_0\}$ , where  $f_{0,uv}$  equal the respective absolute values of Table 1 and are given along the edges of Figure 1b.

Then, we apply the developed iterative algorithm until  $E_i = \{\emptyset\}$ . The iterations of the algorithm equal the number of existing streams from  $x$  to  $y$  and are illustrated in Figure 2.

#### First iteration

1. In  $G_0$ , find the shortest path from  $x$  to  $y$ ,  $\pi_1 = \{xy\}$ . Define its flow as  $\varphi_1 = \min\{f_{0,uv}, uv \in \pi_1\} = f_{0,xy} = 0.635$ . Define stream  $S_1 = (\varphi_1, \pi_1)$  (Figure 2a).

**Table 1. *H* matrix in the network of topical antibiotics without steroids for chronically discharging ears.** Columns correspond to direct comparisons and rows correspond to network meta-analysis (NMA) effects. Direct effects along with their variances and NMA effects with 95% confidence intervals (CIs) are given in the last column. Direct and NMA effects are measured as log odds ratios. **Positive values favour the first treatment.**

	<i>xy</i>	<i>xv</i>	<i>yu</i>	<i>yv</i>	<i>uv</i>	Direct effect	Variance of direct effect	NMA effect (95% CIs)
<b><i>xy</i></b>	0.635	0.365	-0.114	-0.251	-0.114	-2.29	0.42	-1.86 (-3.05,-0.67)
<b><i>xu</i></b>	0.603	0.397	0.632	-0.029	-0.368	–	–	-1.32 (-2.61,-0.02)
<b><i>xv</i></b>	0.545	0.455	0.170	0.375	0.170	0.35	0.63	-0.72 (-1.95,0.52)
<b><i>yu</i></b>	-0.032	0.032	0.745	0.223	-0.255	0.39	0.12	0.54 (-0.07,1.16)
<b><i>yv</i></b>	-0.090	0.090	0.284	0.627	0.284	1.24	0.15	1.14 (0.47,1.81)
<b><i>uv</i></b>	-0.058	0.058	-0.462	0.404	0.538	0.53	0.22	0.60 (-0.12,1.33)

*x*, no treatment; *y*, quinolone antibiotic; *u*, non-quinolone antibiotic; *v*, antiseptic.

- Recalculate the flow of edge  $xy \in \pi_1$  as  $f_{1,xy} = f_{0,xy} - \phi_1 = 0.635 - 0.635 = 0$ . The flow of the rest of the comparisons remains unchanged:  $f_{1,uv} = f_{0,uv} \forall uv \notin \pi_1$  (Figure 2b).
- Define  $E_1$  as the set of edges  $uv$  for which  $f_{1,uv} > 0$ ; edge  $xy$  is removed since its flow is zero,  $E_1 = E_0 \setminus \{xy\}$ . Collect  $f_{1,uv}$  to form the set  $F_1 = \{f_{1,uv} \mid uv \in E_1\}$  (Figure 2c).
- Define  $G_1 = (V, E_1, F_1)$ . As  $E_1 = \{xv, vy, vu, uy\} \neq \{\emptyset\}$ , go to step 1 (Figure 2c).

## Second iteration

- In  $G_1$ , find the shortest path from  $x$  to  $y$ ,  $\pi_2 = \{xv, vy\}$ . Define its flow as  $\phi_2 = \min\{f_{1,uv} \mid uv \in \pi_2\} = f_{1,vy} = 0.251$ . Define stream  $S_2 = (\phi_2, \pi_2)$  (Figure 2d).
- Recalculate the flow of edges  $xv$  and  $vy$  as  $f_{2,xv} = f_{1,xv} - \phi_2 = 0.365 - 0.251 = 0.114$  and  $f_{2,vy} = f_{1,vy} - \phi_2 = 0.251 - 0.251 = 0$ . The flow of the rest of the comparisons remains unchanged:  $f_{2,uv} = f_{1,uv} \forall uv \notin \pi_2$  (Figure 2e).
- Define  $E_2$  as the set of edges  $uv$  for which  $f_{2,uv} > 0$ ; edge  $vy$  is removed since its flow is zero and thus  $E_2 = E_1 \setminus \{vy\}$ . Collect  $f_{2,uv}$  to form the set  $F_2 = \{f_{2,uv} \mid uv \in E_2\}$  (Figure 2f).
- Define  $G_2 = (V, E_2, F_2)$ . As  $E_2 = \{xv, vu, uy\} \neq \{\emptyset\}$ , go to step 1 (Figure 2f).

## Third iteration

- In  $G_2$ , find the shortest path from  $x$  to  $y$ ,  $\pi_3 = \{xv, vu, uy\}$ . Define its flow as  $\phi_3 = \min\{f_{2,uv} \mid uv \in \pi_3\} = 0.114$ . Define stream  $S_3 = (\phi_3, \pi_3)$  (Figure 2g).
- Recalculate the flow of edges  $xv$ ,  $vu$  and  $uy$  as  $f_{3,xv} = f_{2,xv} - \phi_3 = 0.114 - 0.114 = 0$  (Figure 2h).
- Define  $E_3$  as the set of edges  $uv$  for which  $f_{3,uv} > 0$ ; edges  $xv$ ,  $vu$  and  $uy$  are removed since their flow is zero,  $E_3 = E_2 \setminus \{xv, vu, uy\}$ . Collect  $f_{3,uv}$  to form the set  $F_3 = \{f_{3,uv} \mid uv \in E_3\}$  (Figure 2i).
- Define  $G_3 = (V, E_3, F_3)$ . The set of direct edges is  $E_3 = \{\emptyset\}$  and the algorithm is terminated at this point (Figure 2i).

Figure 1c shows the flows of the three streams identified when applying the above algorithm. We then calculate the percentage contributions of each comparison to the ‘ $x$  versus  $y$ ’ NMA treatment effect estimate using Equation 6 (Figure 1d). For instance, to calculate  $p_{xy}$  we first have to identify the relevant paths; these were  $\pi_2$  and  $\pi_3$ . Consequently,

$$p_{xy} = \frac{\phi_2}{|\pi_2|} + \frac{\phi_3}{|\pi_3|} = \frac{0.251}{2} + \frac{0.114}{3} = 0.164 = 16.4\%$$


The calculations for deriving the percentage contributions of the other comparisons are shown in Table 2. Applying the algorithm to all NMA treatment effect estimates we get the entire percentage contribution matrix  $P$ .

## Percentage study contributions

Matrix  $P$  (Table 3) shows the percentage contributions of each direct comparison to each NMA treatment effect estimate. These percentages can be distributed to individual studies within each comparison according to their weights from direct meta-analyses. For example,  $p_{xy} = 63.5\%$  and there are two studies examining the  $xy$  comparison. The individual study weights for the two studies are 0.69 and 1.54 resulting in study percentage contributions of  $\frac{0.69}{0.69+1.54} \times 63.5\% = 19.6\%$  and  $\frac{1.54}{0.69+1.54} \times 63.5\% = 43.8\%$  to the  $xy$  NMA treatment effect estimate. The application of this process to the entire matrix  $P$  leads to the matrix  $P^*$  shown in Table 4. Adjusted weights as proposed by Rücker & Schwarzer<sup>9</sup> are used for multi-arm studies.

## Using percentage study contributions to quantify the impact of a characteristic in a direct comparison

The algorithm translating the  $H$  matrix into study percentage contributions can be applied to quantify the influence that a study-level characteristic has in the estimation of the NMA effects. For instance, if risk of bias judgements for individual studies are available, we can obtain an approximation of the percentage of each NMA treatment effect estimate that is coming from studies with a ‘high’, ‘moderate’, or ‘low’ risk of bias. Salanti *et al.* suggested the visualisation of this information using a bar plot, in which direct comparisons



**Figure 2.** Illustration of the steps of the algorithm for approximating percentage contributions per comparison in the network of topical antibiotics without steroids for chronically discharging ears focusing on the comparison 'x versus y'. Treatment labels: **x**, no treatment; **y**, quinolone antibiotic; **u**, non-quinolone antibiotic; **v**, antiseptic.



**Table 2. Percentage contributions of direct comparisons to the 'x versus y' network meta-analysis treatment effect in the network of topical antibiotics without steroids for chronically discharging ears.**

	<i>xy</i>	<i>xv</i>	<i>yu</i>	<i>yv</i>	<i>uv</i>
<b><i>xy</i></b>	$p_{xy} = \frac{\varphi_1}{ \pi_1 } = 63.5\%$	$p_{xv} = \frac{\varphi_2}{ \pi_2 } + \frac{\varphi_3}{ \pi_3 } = 16.4\%$	$p_{yu} = \frac{\varphi_3}{ \pi_3 } = 3.8\%$	$p_{yv} = \frac{\varphi_2}{ \pi_2 } = 12.6\%$	$p_{uv} = \frac{\varphi_3}{ \pi_3 } = 3.8\%$

x, no treatment; y, quinolone antibiotic; u, non-quinolone antibiotic; v, antiseptic.

**Table 3. Percentage contribution matrix *P* for the network of topical antibiotics without steroids for chronically discharging ears.** Cells show the percentage contribution of direct comparisons indicated in the column to the network meta-analysis treatment effects indicated in the rows.

	<i>xy</i>	<i>xv</i>	<i>yu</i>	<i>yv</i>	<i>uv</i>
<b><i>xy</i></b>	63.5%	16.4%	3.8%	12.6%	3.8%
<b><i>xu</i></b>	30.1%	19.4%	31.1%	1%	18.4%
<b><i>xv</i></b>	24.4%	45.5%	5.7%	18.8%	5.7%
<b><i>yu</i></b>	1.1%	1.1%	74.5%	11.1%	12.2%
<b><i>yv</i></b>	4.5%	4.5%	14.2%	62.7%	14.2%
<b><i>uv</i></b>	1.9%	1.9%	22.1%	20.2%	53.8%

x, no treatment; y, quinolone antibiotic; u, non-quinolone antibiotic; v, antiseptic.

**Table 4. Study percentage contribution matrix *P\** for the network of topical antibiotics without steroids for chronically discharging ears.** Cells show the percentage contribution of individual studies indicated in the column to the network meta-analysis treatment effects indicated in the rows.

	Study 1	Study 2	Study 3	Study 4	Study 5	Study 6	Study 7	Study 8	Study 9	Study 10	Study 11	Study 12	Study 13
<b><i>xy</i></b>	19.7	63.4	2.8	0.5	0.6	0.4	0.6	0.7	2.7	1.3	0.8	2.3	4.2
<b><i>xu</i></b>	9.3	40.4	8.8	4.4	5.3	3.5	5.1	5.4	6.9	6.5	3.9	0.2	0.3
<b><i>xv</i></b>	7.6	67.1	4.2	0.8	1	0.6	0.9	1	4.1	2	1.2	3.4	6.2
<b><i>yu</i></b>	0.3	4.63	13.6	10.5	12.7	8.4	12.2	12.9	12.2	4.3	2.6	2	3.7
<b><i>yv</i></b>	1.4	23.5	12.1	2	2.4	1.6	2.3	2.4	12.2	5	3	11.3	20.7
<b><i>uv</i></b>	0.6	8.4	19	3.1	3.8	2.5	3.6	3.8	14.4	19.1	11.5	3.6	6.7

x, no treatment; y, quinolone antibiotic; u, non-quinolone antibiotic; v, antiseptic.

of the same risk of bias level have been grouped<sup>3</sup>. **Figure 3** shows such a bar plot using the algorithm described in this paper and distributing comparison percentage contributions to study percentage contributions; inspecting **Figure 3** can support judgements regarding the importance of study limitations for different NMA treatment effect estimates. For instance, studies with high risk of bias contribute more than 50% in the estimation of the 'u versus v' comparison, potentially reducing the confidence that we can place in this particular NMA treatment effect estimate.

### Percentage contributions of direct comparisons in a large complex network of interventions


So far, we have illustrated how to derive percentage contributions for a network with four treatments. However, the algorithm can be straightforwardly applied to large networks of any structure, as soon as the involved treatments are connected. Consider for example a large network examining antimanic drugs

(**Figure 4**)<sup>11</sup>. Let us concentrate on the comparison PLA versus OLA ('placebo versus olanzapine'); the algorithm starts by applying step 0 and constructing network  $G_0$ . Then, we continue by finding the shortest path in the first iteration, which corresponds to the direct comparison, and define its flow and stream  $S_1 = (\varphi_1, \pi_1)$ . The number of algorithm's iterations is equal to the number of streams from placebo to olanzapine, which turns out to be 16. The resulting entire percentage matrix is given in **Supplementary File 2**.


**Dataset 1. Outcome data from the example network of topical antibiotics for the treatment of chronic otitis media with ear discharge in patients with eardrum perforations<sup>7</sup>**

<http://dx.doi.org/10.5256/f1000research.14770.d203174>

Data labels: study, name of individual studies; id, id of the individual studies; t; treatment; r, number of events; n, sample size; rob, risk of bias per study.



**Figure 3.** Bar plot showing the study percentage contributions of direct comparisons with low (green), moderate (yellow) and high (red) risk of bias. The bar plot has been produced in CINeMA (Confidence In Network Meta-Analysis) software<sup>12</sup>. Studies are synthesized using the random effects model. *x*, no treatment; *y*, quinolone antibiotic; *u*, non-quinolone antibiotic; *v*, antiseptic.



**Figure 4.** Network plot for the network of antimanic drugs. ASE, asenapine; ARI, aripiprazole; PLA, placebo; HAL, haloperidol; QUE, quetiapine; LITH, lithium; ZIP, ziprasidone; OLA, olanzapine; DIV, divalproex; RIS, risperidone; CARB, carbamazepine; LAM, lamotrigine; PAL, paliperidone; TOP, topiramate; ASE, asenapine.

## Discussion

In this paper, we present a new approach to derive percentage contributions of individual studies to the treatment effect estimates in NMA. We made use of the fact that the composition of network treatment effect estimates can be interpreted as a flow of evidence. An assumption that underlies our algorithm is the equal split of the stream flow to the involved comparisons. Although indirect effects are not weighted averages, we find this approximation to be a pragmatic approach that reasonably reflects the amount that each comparison contributes to network effects.

Applying the algorithm to networks of interventions can be used to quantify the contribution of potential study limitations to the

NMA treatment effect estimates. Study limitations may lead to biased NMA treatment effect; however, the amount and direction of bias in the NMA treatment effect as a result of the within-study bias is not straightforward to define and is not currently accommodated within the percentage contribution matrix. First, a single biased trial may affect an entire indirect route; thus, even if its percentage contribution is small, its consequences in the estimation of the NMA treatment effect may be important. Second, the direction of bias across studies involved in a stream may vary. For example, bias in two comparisons in the same stream may either cancel out or add-up in favor of one of the two treatments. We aim to extend the methods presented in this paper to develop a network meta-regression model that will use the

direction and the amount of bias to determine whether and how much NMA treatment effect estimates will be biased as the result of within-study bias.

Alternative methods to derive the relative contribution of all sources of evidence have been developed<sup>4,12,13,14</sup>. An alternative approach has been proposed to derive percentage study weights in a variety of meta-analysis models, including meta-regression, network meta-analysis and individual patient data meta-analysis<sup>10</sup>. This approach is based on the decomposition of Fisher's information matrix and thus the derived weights are not influenced by the network structure. Further investigation of the degree of agreement between our algorithm and that of Riley *et al.*<sup>10</sup> would be of interest.

In the example implemented in the Application, there is no other possible set of paths, and associated streams, that could be selected from  $x$  to  $y$  in order to partition the inflow of  $x$ :  $\pi_1$ ,  $\pi_2$  and  $\pi_3$  is the only possible set of streams (Figure 1c). Thus, even if we were taking paths using different criteria, i.e. from longest to shortest, according to values from the  $H$  matrix or even randomly, the percentage contributions given in Table 2 would be identical. However, cases exist where the selection of paths does influence the derivation of the  $P$  matrix. In Supplementary File 3, we elaborate on the selection of direct paths in the algorithm and discuss some alternative modifications of the algorithm. We are planning to examine the properties of the different approaches in greater detail in a follow up project.

We offer an R package<sup>11</sup>, which we also use in the software application CINeMA (Confidence In Network Meta-Analysis)<sup>12</sup>, that aims to simplify the evaluation of confidence in the findings

from NMA. While CINeMA largely follows the framework previously developed by Salanti *et al.*<sup>3</sup>, the refinement of several methodological aspects is currently under development. Core aspects of the approach include the consideration of the relative contributions of each direct comparison to each NMA treatment effect estimate. To this end, CINeMA uses the percentage contribution matrix as described in this paper. The command *netweight* in Stata has also been updated to use the described approach.

We believe that the approach described in this paper is a useful and novel addition to network meta-analysis methodology, which allows the consistent derivation of the percentage contributions of direct evidence from individual studies to network treatment effects.

### Data availability

**Dataset 1: Outcome data from the example network of topical antibiotics for the treatment of chronic otitis media with ear discharge in patients with eardrum perforations<sup>7</sup>.** Data labels: **study**, name of individual studies; **id**, id of the individual studies; **t**, treatment; **r**, number of events; **n**, sample size; **rob**, risk of bias per study. DOI: [10.5256/f1000research.14770.d203174](https://doi.org/10.5256/f1000research.14770.d203174)<sup>13</sup>.

### Grant information

TP received funding from a Campbell Collaboration Method Grant [grant no. CMG2.04].

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

### Supplementary material

**Supplementary File 1. Proof that the sum of all outflows from the source is equal to the sum of all inflows to the sink and both are 1.**

[Click here to access the data.](#)

**Supplementary File 2. Percentage contribution matrix  $P$  for the network of antimanic drugs. Cells show the percentage contribution of direct comparisons indicated in the column to the network meta-analysis treatment effects indicated in the rows.** ASE, asenapine; ARI, aripiprazole; PLA, placebo; HAL, haloperidol; QUE, quetiapine; LITH, lithium; ZIP, ziprasidone; OLA, olanzapine; DIV, divalproex; RIS, risperidone; CARB, carbamazepine; LAM, lamotrigine; PAL, paliperidone; TOP, topiramate; ASE, asenapine.

[Click here to access the data.](#)

### Supplementary File 3

Considerations on the selection of streams

[Click here to access the data.](#)

## References

1. Eichler HG, Thomson A, Eichler I, *et al.*: **Assessing the relative efficacy of new drugs: an emerging opportunity.** *Nat Rev Drug Discov.* 2015; 14(7): 443–4.  
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Jansen JP, Trikalinos T, Cappelleri JC, *et al.*: **Indirect treatment comparison/ network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report.** *Value Health.* 2014; 17(2): 157–73.  
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Salanti G, Del Giovane C, Chaimani A, *et al.*: **Evaluating the quality of evidence from a network meta-analysis.** *PLoS One.* 2014; 9(7): e99682.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. König J, Krahn U, Binder H: **Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons.** *Stat Med.* 2013; 32(30): 5414–29.  
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Lu G, Welton NJ, Higgins JP, *et al.*: **Linear inference for mixed treatment comparison meta-analysis: A two-stage approach.** *Res Synth Methods.* 2011; 2(1): 43–60.  
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Rücker G: **Network meta-analysis, electrical networks and graph theory.** *Res Synth Methods.* 2012; 3(4): 312–24.  
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Macfadyen CA, Acuin JM, Gamble C: **Topical antibiotics without steroids for chronically discharging ears with underlying eardrum perforations.** *Cochrane Database Syst Rev.* 2005; (4): CD004618.  
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Cormen TH, editor: **Introduction to algorithms.** 2. ed., 8. printing, Cambridge, Mass.: MIT Press [u.a.]; 2007; 1180.  
[Reference Source](#)
9. Rücker G, Schwarzer G: **Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis.** *Stat Med.* 2014; 33(25): 4353–69.  
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Riley RD, Ensor J, Jackson D, *et al.*: **Deriving percentage study weights in multi-parameter meta-analysis models: with application to meta-regression, network meta-analysis and one-stage individual participant data models.** *Stat Methods Med Res.* 2017; 962280216688033.  
[PubMed Abstract](#) | [Publisher Full Text](#)
11. **Flow contribution R package [Internet].**  
[Reference Source](#)
12. **Confidence In Network Meta-Analysis [Internet].**  
[Reference Source](#)
13. Papakonstantinou T, Nikolakopoulou A, Rücker G, *et al.*: **Dataset 1 in: Estimating the contribution of studies in network meta-analysis: paths, flows and streams.** *F1000Research.* 2018.  
<http://www.doi.org/10.5256/f1000research.14770.d203174>

# Open Peer Review

Current Referee Status:



Version 1

Referee Report 16 August 2018

doi:10.5256/f1000research.16071.r37273



**John R. Thompson** 

Department of Health Sciences, University of Leicester, Leicester, UK

This report is also available as a [separate PDF](#).

I have no special knowledge of the measurement of information flow in a network meta-analysis and so I read this paper as a biostatistician with a general interest in meta-analysis.

I like the idea of associating a descriptive measure of importance to each edge in a network and the authors of this paper present an interesting step in that direction, though my feeling is that this proposal will not turn out to be the final solution. I have two areas of concern, one is to do with terminology and the other with the scope of applicability of the proposal solution.

In criticising the terminology, I have to accept that the authors are largely following common practice and so my criticisms are partly aimed at the meta-analysis community. None the less there were three things that irritated me. Firstly, throughout the paper, proportions are referred to as percentages. Next, the title of the paper says it is about "the contribution of studies in network meta-analysis" while actually it is about the contribution of different effect estimates. Finally, the measure adopted is the weight given to each effect estimate when calculating the pooled estimate. In this paper and elsewhere in the meta-analysis literature, this weight is called a contribution. Perhaps I am being too pedantic but the weight and contribution are different ideas and it does not help with the terminology confuses them.

Now the proposed method. Taking the example from the paper, the authors note that the pooled estimate of the xy effect can be calculated using [equation 1](#), where  $\theta_{xvy}^l$  is the indirect estimate of xy along the path xy. Further it is true, at least for this example, that  $\sum L_{i\phi_i} = 1$  where  $L_i$  is the length of the path. So we can attach the weights  $\phi$  to the edges of the network, sum them when an edge contributes to more than one estimate and the resulting weights will sum to one over the whole network.

This argument works for the example presented in the paper but it is not clear to me what conditions have to hold for it to work generally. The authors note in the paper that including a multi-arm trial in the meta-analysis would cause a problem, presumably because some of the direct or indirect estimates would not be independent. Are there any other conditions that have to hold? For example, can we have any structure of random effects in the meta-analysis model? What about the Bayesian models that are often used for network meta-analysis?

The authors take the matrix, H, which projects individual estimates such as xy, xy, uy, etc. into their

predicted values under the meta-analysis model and they present an algorithm for converting those values into weights that are equivalent to the  $\phi$ 's. The algorithm is sensible and works for the simple example in the paper but one is again left wondering whether or not it works under all circumstances. After all, the algorithm is presented without any proof that it works.

My own feeling is that a contribution is best measured by the sledgehammer approach of analysing the network with and without a particular edge, but the authors' suggested approach is much less computationally demanding and I think that it would be appreciated by many applied researchers provided they were certain that it could be safely used with their particular network and their particular meta-analysis model.

**Is the rationale for developing the new method (or application) clearly explained?**

Yes

**Is the description of the method technically sound?**

Yes

**Are sufficient details provided to allow replication of the method development and its use by others?**

Yes

**If any results are presented, are all the source data underlying the results available to ensure full reproducibility?**

Partly

**Are the conclusions about the method and its performance adequately supported by the findings presented in the article?**

Partly

**Competing Interests:** No competing interests were disclosed.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Referee Report 14 August 2018

doi:10.5256/f1000research.16071.r36470



**Annette M. O'Connor** 

Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA

This paper described an updated approach to deriving the percentage contributions of the direct comparison used in treatment estimates. In the interests of full disclosure, I am not a statistician and was reviewing from the view point of an applied user of NMA. There are several papers on this topic in recent years, and it is an active body of work in this area. The article is straightforward to read, although made considerably more readable if one is aware of the content in references, 3,4 and 5.



I have to admit that this is an example of why I appreciate the open review system. I enjoyed the paper and found it easy to read and follow, but the others reviewer's comments were a significant contribution also. I don't have any additional critique of the proposed approach, but I look forward to seeing how the investigators address those or provided some discussion, as this would help the less statistically inclined reader like me. Again, the reason I wanted this, is that I am an applied user and such discussions are very helpful. In particular, I would like to have seen some discussion of the 1st comment. I would also like to see if the comment about Figure 3 could be incorporated - perhaps not feasible.

Concerning the approach to calculating the % contribution and how to weight the flows, I came away with the impression that the decision of equal split of the stream flow as arbitrary (perhaps not precisely the correct term) or perhaps pragmatic is better. Therefore, it is not surprising this is a debatable approach. Again, this was another reason why I am looking forward to see the investigators responses to the 1st reviewer's comments. I agree that the comparison of the methods of deriving the percentage contribution would be of interest but was not expecting that to be included. I look forward to this comparison being published.

**Is the rationale for developing the new method (or application) clearly explained?**

Yes

**Is the description of the method technically sound?**

Yes

**Are sufficient details provided to allow replication of the method development and its use by others?**

Yes

**If any results are presented, are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions about the method and its performance adequately supported by the findings presented in the article?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Referee Expertise:** Epidemiology, infectious diseases, research synthesis

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Referee Report 13 June 2018

doi:10.5256/f1000research.16071.r34177



**Jochem König** 

Division of Paediatric Epidemiology, Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI), Johannes Gutenberg University Medical Center, Mainz, Germany

1. The authors undertake a redefinition of the term 'percentage contribution' in network meta-analysis. In ordinary meta-analysis of randomized clinical trials, pooled estimates of a treatment effect can be represented as a weighted mean of treatment effects from all contributing trials. Weights are positive and sum to one and naturally constitute the 'percentage contribution' of each study. In network meta-analysis treatment effect estimates are defined for all pairs of treatments. Each can be represented as a two-stage estimate, firstly pooling all trials comparing the same set of treatments, respectively, which gives direct effect estimates, and then pooling direct estimates into a network based mixed treatment comparison. The linear coefficients, used in the second stage constitute the 'contribution of direct evidence to a network based comparison'. They can be read off, from the H matrix, as described by the authors. They share some but not all aspects with weights of a two-armed meta-analysis. Aspects shared in some sense are the flow properties described by the authors and in citation [4]. The aspect not shared, is that summation to one.

Indeed, in a purely linear graph connecting two extreme treatments through a chain of, say 10, pairwise intermediary comparisons, the network estimate is the sum of all direct effects. Any bias present in one direct effect estimate translates 1:1 into the network based estimate. Accordingly, the entries of the H matrix are all equal to 1 in the relevant row.

Both, Salanti [3] and the present paper aim to rescale or transform the rows of the H matrix in order to achieve a 'sum to one' condition. In the case of the linear graph, the percentage contribution is 10% for each direct comparison. I am not convinced, that this number adequately captures the role of each direct effect estimate in this example.

Consider now, an example where two treatments are connected through three paths with one, two, and three edges, respectively, each with flow  $1/3$ . Then each direct comparison has the same influence on the network based treatment effect estimate: A bias of 1 unit in one direct estimate translates into a bias of  $1/3$  unit in the network based estimate. These proportions are conserved in Salanti's notion of percentage contribution, but not so in the newly introduced concept. Salanti [3] attaches a percentage contribution of  $1/6$  to each comparison just as if we had pooled six equally precise trials comparing the same pair of treatments. But the influence of direct comparisons is different in this network and should be characterized by the number  $1/3$ .

That is why I have objections against Salanti's [3] concept of percentage contribution and even more so against the newly introduced concept, which attaches unequal contribution quantities of  $1/9$ ,  $1/6$  and  $1/3$ , respectively.

The new method should not be introduced into routine of network meta-analysis. If this paper is going to be indexed, its draw backs and caveats should be very clearly set out.

2. The concept of streams is a nice one. It allows to represent a network based treatment effect as a weighted sum of a direct and indirect effect estimates each corresponding to one path from source to sink. Note however that these effects are stochastically interdependent and hence, the aggregation of streams is different from the usual process of pooling evidence.
3. To be somewhat less destructive, I propose to arrange the network graph with the source to the left and the sink to the right and all other vertices placed, such that all directed edges point from left to right. Then, due to the flow properties, any vertical cross-section gives a set of flows that sum to one. In that sense, the untransformed rows of the H matrix already contain percentage

contributions. Displays used to present voter hiking can be used to represent these flows (see e.g. [www.zeit.de/politik/deutschland/2017-05/waehlerwanderung-nrw-landtagswahl-cdu-spd-fdp](http://www.zeit.de/politik/deutschland/2017-05/waehlerwanderung-nrw-landtagswahl-cdu-spd-fdp)).

4. I propose to modify Table 3 and Figure 3 in a way that the direction of influence becomes clear. Does a positive bias in one contributing direct effect translate into a positive or negative bias of the network based effect estimate? The colored fields in Figure 3 could be labelled with meaningfully ordered pairs of treatment letters.
5. Discussion “The calculation of the percentages uses the estimated variances of direct effects and thus incorporate associated uncertainty in their estimation.”  
Note however, that in a linear network each direct effect estimate contributes equally, irrespective of the size and precision of the study.
6. Discussion “Applying the algorithm to networks of interventions can be used to quantify the contribution of potential study limitations to the NMA treatment effect estimates.”  
The two stage approach discussed in this paper is not essential. Both the flows and the percentage contribution defined in the paper can be distributed to single trials according to the weights used when pooling them into direct effect estimates. Then the risk of bias of single trials can be analyzed. A display similar to Figure 3 is possible that contains separately colored fields for individual studies.
7. Discussion, 2<sup>nd</sup> paragraph: Concerning multi-armed designs, König et al.[4] have defined the flow into and out of the vertices in a way that does not depend on the choice of reference treatment.

Supplementary File 3:

1st paragraph: What is the vector space of  $G_{xy}$  over  $R$ ?

2nd paragraph: ‘The number of directed paths’ obviously refers to the number of directed paths „which suffice to ‘spend’ the flow from source to sink”.

The authors state that, if no bridges exist, this number equals to  $df+1$ . However, it depends on the flows, too. Consider a network composed of two squares connected at one vertex. It has  $df=2$  inconsistency degrees of freedom and generally 3 paths are needed to spend the flow between the two most distant vertices. However, if all edges have equal flows, only two paths are needed. Moreover, the connecting vertex has the same effect as the bridging edges. Hence the argument has to be extended to the case of graphs that can be split by cutting through a vertex.

Note also, that a network estimate that compares treatments from different subgroups of treatments connected through a bridge or a ‘breaking’ vertex can be written as the sum of three respective two subnetwork effect estimates: one comparing the source treatment to the bridge post, one for the bridge, if present, and one comparing the second bridge post to the sink. Because it is an unweighted sum, the contribution of the three (or two) summands should be equal.

**Is the rationale for developing the new method (or application) clearly explained?**

Yes

**Is the description of the method technically sound?**

Yes

**Are sufficient details provided to allow replication of the method development and its use by others?**

Yes

**If any results are presented, are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions about the method and its performance adequately supported by the findings presented in the article?**

Partly

**Competing Interests:** No competing interests were disclosed.

**I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 19 Aug 2018

**Adriani Nikolakopoulou**, Institute of Social and Preventive Medicine, Switzerland

We are grateful to Dr. Jochem König for the time and effort he spent to review our paper. We believe that his valuable comments and suggestions have substantially improved the manuscript. We have addressed all his comments and revised the paper accordingly. Below you can find detailed replies to the reviewer's suggestions and comments.

**Referee Report 13 Jun 2018**

**Jochem König**, Division of Paediatric Epidemiology, Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI), Johannes Gutenberg University Medical Center, Mainz, Germany

**Approved with Reservations**

1. The authors undertake a redefinition of the term 'percentage contribution' in network meta-analysis. In ordinary meta-analysis of randomized clinical trials, pooled estimates of a treatment effect can be represented as a weighted mean of treatment effects from all contributing trials. Weights are positive and sum to one and naturally constitute the 'percentage contribution' of each study. In network meta-analysis treatment effect estimates are defined for all pairs of treatments. Each can be represented as a two-stage estimate, firstly pooling all trials comparing the same set of treatments, respectively, which gives direct effect estimates, and then pooling direct estimates into a network based mixed treatment comparison. The linear coefficients, used in the second stage constitute the 'contribution of direct evidence to a network based comparison'. They can be read off, from the H matrix, as described by the authors. They share some but not all aspects with weights of a two-armed meta-analysis. Aspects shared in some sense are the flow properties described by the authors and in citation [4]. The aspect not shared, is that summation to one.

Indeed, in a purely linear graph connecting two extreme treatments through a chain of, say 10, pairwise intermediary comparisons, the network estimate is the sum of all direct effects. Any bias present in one direct effect estimate translates 1:1 into the network based estimate. Accordingly, the entries of the H matrix are all equal to 1 in the relevant row.

Both, Salanti [3] and the present paper aim to rescale or transform the rows of the H matrix in order to achieve a 'sum to one' condition. In the case of the linear graph, the percentage contribution is 10% for each direct comparison. I am not convinced, that this number adequately captures the role of each direct effect estimate in this example.

Consider now, an example where two treatments are connected through three paths with one, two, and three edges, respectively, each with flow 1/3. Then each direct comparison has the same influence on the network based treatment effect estimate: A bias of 1 unit in one direct estimate translates into a bias of 1/3 unit in the network based estimate. These proportions are conserved in Salanti's notion of percentage contribution, but not so in the newly introduced concept. Salanti [3] attaches a percentage contribution of 1/6 to each comparison just as if we had pooled six equally precise trials comparing the same pair of treatments. But the influence of direct comparisons is different in this network and should be characterized by the number 1/3.

That is why I have objections against Salanti's [3] concept of percentage contribution and even more so against the newly introduced concept, which attaches unequal contribution quantities of 1/9, 1/6 and 1/3, respectively.

**The new method should not be introduced into routine of network meta-analysis. If this paper is going to be indexed, its draw backs and caveats should be very clearly set out.**

Thank you for this insightful comment. We agree with the point you make which we find that enlightens potential applications or extensions of the presented method to account for bias in network meta-analysis.

We would like to make a distinction between '*representation of the contribution of pieces of evidence in a 0 to 1 scale*' and '*using this percentage contributions to represent and measure the impact and directionality of potential bias*'. In this paper, we focus on the first aspect of translating the matrix into percentages and we subsequently apply it to depict the contribution of pieces of evidence according to a study characteristic. Our aim is to give a representation of the evidence that each comparison –or study, see our response to comment 6 below- contributes to the estimation of each NMA treatment effect without considering how this evidence could bias the results. Note that the bar plot of figure 3 gives a picture of the contribution of high, moderate or low risk of bias evidence without giving insight on the amount or direction of bias.

Quantification of bias in the direct evidence and its impact on the NMA estimates is subject of further research but not addressed within this paper. We have now added a paragraph in the Discussion to highlight the limitations of the presented method as you recommend. The paragraph reads:

*"Study limitations may lead to biased NMA treatment effect; however, the amount and direction of bias in the NMA treatment effect as a result of the within-study bias is not straightforward to define and is not currently accommodated within the percentage contribution matrix. First, a single biased*

*trial may affect an entire indirect route; thus, even if its percentage contribution is small, its consequences in the estimation of the NMA treatment effect may be important. Second, the direction of bias across studies involved in a stream may vary. For example, bias in two comparisons in the same stream may either cancel out or add-up in favor of one of the two treatments. We aim to extend the methods presented in this paper to develop a network meta-regression model that will use the direction and the amount of bias to determine whether and how much NMA treatment effect estimates will be biased as the result of within-study bias."*

**2. The concept of streams is a nice one. It allows to represent a network based treatment effect as a weighted sum of a direct and indirect effect estimates each corresponding to one path from source to sink. Note however that these effects are stochastically interdependent and hence, the aggregation of streams is different from the usual process of pooling evidence.**

Thank you for this comment; indeed the aggregation of streams is not equivalent to the aggregation of studies in a pairwise meta-analysis. We write in 'Percentage contributions of direct comparisons':

*"It can be shown that an NMA effect is a linear combination of the direct effects combined within paths."*

And we now added in the same section:

*"Equation 5 represents  $\theta_{xy}^N$  as a weighted sum of direct and two indirect effect estimates; the effects are stochastically interdependent and, hence, their aggregation is different from the aggregation of studies in a pairwise meta-analysis."*

**3. To be somewhat less destructive, I propose to arrange the network graph with the source to the left and the sink to the right and all other vertices placed, such that all directed edges point from left to right. Then, due to the flow properties, any vertical cross-section gives a set of flows that sum to one. In that sense, the untransformed rows of the H matrix already contain percentage contributions. Displays used to present voter hiking can be used to represent these flows (see e.g. [www.zeit.de/politik/deutschland/2017-05/waehlerwanderung-nrw-landtagswahl-cdu-spd-fdp](http://www.zeit.de/politik/deutschland/2017-05/waehlerwanderung-nrw-landtagswahl-cdu-spd-fdp) ).**

Thank you, we agree that horizontal representation is more intuitive. We re-arranged figures 1 and 2 accordingly.

**4. I propose to modify Table 3 and Figure 3 in a way that the direction of influence becomes clear. Does a positive bias in one contributing direct effect translate into a positive or negative bias of the network based effect estimate? The colored fields in Figure 3 could be labelled with meaningfully ordered pairs of treatment letters.**

Thank you very much for this comment which we believe is related to your comment 1. We agree that such a representation would be useful but we believe it could confuse readers with respect to the scope of this paper which is not to quantify the impact of within-study bias. As said in comment 1, the scope of this paper is to represent the percentage contributions of each piece of evidence; combining this information with information of study characteristics in a figure such as figure 3 may



be a useful representation of the contribution of these characteristics to the estimation of NMA treatment effects. The influence of these characteristics, though, is not straightforwardly derived and it is subject to further research. Thus, we would prefer to leave Table 3 and Figure 3 unmodified and construct such representations of the direction of bias in future work where we aim to develop models to account for study-level bias using the presented methodology.

Please also see the reply to comment 1 and the addition to the Discussion.

**5. Discussion “The calculation of the percentages uses the estimated variances of direct effects and thus incorporate associated uncertainty in their estimation.”**

**Note however, that in a linear network each direct effect estimate contributes equally, irrespective of the size and precision of the study.**

We agree this statement is confusing and hence deleted this phrase from the Discussion. The paragraph now reads:

*“In this paper, we present a new approach to derive percentage contributions of individual studies to the treatment effect estimates in NMA. We made use of the fact that the composition of network treatment effect estimates can be interpreted as a flow of evidence. An assumption that underlies our algorithm is the equal split of the stream flow to the involved comparisons. Although indirect effects are not weighted averages, we find this approximation to be a pragmatic approach that reasonably reflects the amount that each comparison contributes to network effects.”*

**6. Discussion “Applying the algorithm to networks of interventions can be used to quantify the contribution of potential study limitations to the NMA treatment effect estimates.”**

**The two stage approach discussed in this paper is not essential. Both the flows and the percentage contribution defined in the paper can be distributed to single trials according to the weights used when pooling them into direct effect estimates. Then the risk of bias of single trials can be analyzed. A display similar to Figure 3 is possible that contains separately colored fields for individual studies.**

Thank you for this comment; we agree that such a distribution of percentage contributions to single trials is possible and relevant and we have updated the paper accordingly.

1. We added an extra paragraph/subsection ‘Percentage study contributions’ where we elaborate on the process you describe. The new paragraph reads:

*“Matrix  $\mathbf{P}$  (Table 3) shows the percentage contributions of each direct comparison to each NMA treatment effect estimate. These percentages can be distributed to individual studies within each comparison according to their weights from direct meta-analyses. For example,  $p_{xy}=63.5\%$  and there are two studies examining the  $xy$  comparison. The individual study weights for the two studies are 0.69 and 1.54 resulting to study percentage contributions of  $(0.69/(0.69+1.54))*63.5\%=19.6\%$  and  $(1.54/(0.69+1.54))*63.5\%=43.8\%$  to the  $xy$  NMA treatment effect estimate. The application of this process to the entire matrix  $\mathbf{P}$  leads to the matrix  $\mathbf{P}^*$  shown in Table 4. Adjusted weights as proposed by Rücker & Schwarzer (9) are used for multi-arm studies.”*

2. Section ‘Using percentage contributions to quantify the impact of a characteristic in a direct comparison’ has been renamed to ‘Using percentage study contributions to quantify the impact of a characteristic in a direct comparison’ and follows the new ‘Percentage study contributions’

section. Text has been updated to refer to studies instead of direct comparisons and Figure 3 (and the new Table 4) now displays percentage study contributions to NMA treatment effect estimates.

3. The CINeMA (Confidence In Network Meta-Analysis) <http://cinema.ispm.ch/> software has also been updated to display the bar chart using study contributions.

4. The first sentence of the Discussion now reads:

*"In this paper, we present a new approach to derive percentage contributions of individual studies to the treatment effect estimates in NMA."*

**7. Discussion, 2<sup>nd</sup> paragraph: Concerning multi-armed designs, König et al.[4] have defined the flow into and out of the vertices in a way that does not depend on the choice of reference treatment.**

Thank you for this comment, we could indeed use the **H** matrix as described in section 3.3.1 of König et al.[4] (and implemented in netmeta as H.tilde) for multi-arm designs; some concerns about the interpretability of such a matrix have previously precluded us of doing so. In fact, the algorithm could be applied to any **H** matrix as long as its rows have the flow properties described in König et al.[4] and in our section 'Comparison graph'. We have removed the discussion on multi-arm trials from the Discussion and added the following paragraph at the end of the Methods section:

*"The starting point for the developed algorithm was a simplified version of the **H** matrix that does not consider the correlation induced by multi-arm trials. Alternatively, one could use the matrix as described by König et al. (4) that properly accommodates multi-arm designs. Note that any matrix whose rows can be interpreted as flow networks can be used as the starting point of the algorithm."*

### **Supplementary File 3:**

#### **1st paragraph: What is the vector space of $G_{xy}$ over $R$ ?**

Thank you for this comment; as it was not clear and in order to simplify this part, we eliminated the notions of 'vector space' and 'basis' in the document. It now reads:

"However, in the general case, the number of paths used in the algorithm is smaller than the number of elements of  $\Pi$ . The number of directed paths which suffice to 'spend' the flow from source to sink is less or equal to  $df+1$  where  $df$  is the inconsistency degrees of freedom in the Lu and Ades inconsistency model (1),  $df=D-T+1$ ."

**2nd paragraph: 'The number of directed paths' obviously refers to the number of directed paths „which suffice to 'spend' the flow from source to sink".**

Thank you, we corrected it.

**The authors state that, if no bridges exist, this number equals to  $df+1$ . However, it depends on the flows, too. Consider a network composed of two squares connected at one vertex. It has  $df=2$  inconsistency degrees of freedom and generally 3 paths are needed to spend the flow between the two most distant vertices. However, if all edges have equal flows, only two paths are needed. Moreover, the connecting vertex has the same effect as the bridging edges. Hence the argument has to be extended to the case of**

graphs that can be split by cutting through a vertex.

Note also, that a network estimate that compares treatments from different subgroups of treatments connected through a bridge or a 'breaking' vertex can be written as the sum of three respective two subnetwork effect estimates: one comparing the source treatment to the bridge post, one for the bridge, if present, and one comparing the second bridge post to the sink. Because it is an unweighted sum, the contribution of the three (or two) summands should be equal.

Thank you very much for these interesting notes with which we totally agree. We extended the 'Number of directed paths' section in Supplementary File 3 to include discussion on the 'breaking' vertex situation and the consequences you describe. In particular we wrote:

*"Another situation where the number of directed paths which suffice to 'spend' the flow from source to sink is less than  $df+1$  elements occurs when a vertex has at least two inflows and two outflows, all equal between them. In such a situation the flow from source to sink may be spent in less than  $df+1$  directed paths. Such a vertex will be called breaking vertex. Note that an NMA treatment effect estimate for treatments separated by a bridge or a breaking vertex (say treatments  $x$  and  $y$ ) can be seen as an "indirect" comparison through either the intermediate bridge (constituted by treatments  $b_1$  and  $b_2$ ) or the intermediate breaking vertex ( $b_0$ ).*

*In particular, in the case of a bridge, the NMA treatment effect estimate is derived as*

$$\theta_{xy}^N = \theta_{xb1}^N + \theta_{b1b0}^N + \theta_{b2y}^N$$

*and in the case of a breaking vertex the NMA treatment effect estimate is*

$$\theta_{xy}^N = \theta_{xb0}^N + \theta_{b0y}^N$$

*It is, thus, implied that in such a case the separate subnetworks contribute equally to the estimation of  $\theta_{xy}^N$ .*"

- Is the rationale for developing the new method (or application) clearly explained?

Yes

- Is the description of the method technically sound?

Yes

- Are sufficient details provided to allow replication of the method development and its use by others?

Yes

- If any results are presented, are all the source data underlying the results available to ensure full reproducibility?

Yes

- Are the conclusions about the method and its performance adequately supported by the findings presented in the article?

Partly

**Competing Interests:** No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

**Competing Interests:** No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact [research@f1000.com](mailto:research@f1000.com)

F1000Research